Company: LENZ
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001815776-25-000032
Chunk: 290

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 290
---
icit)Series A Convertible PreferredStockSeries A-1 ConvertiblePreferred StockSeries B Convertible PreferredStockClass B Convertible CommonStockCommon StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)Stockholders' Equity(Deficit)SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance as of December 31, 2023(1)21,977,282$44,621 2,950,548$9,893 28,019,181$82,976 2,744,184$5,900 1,969,360$10 $2,517 $(95,245)$6 $(92,712)Conversion of convertible preferred stock and Class B convertible common stock to common stock as a result of the Merger and reset to par of $0.00001(21,977,282)(44,621)(2,950,548)(9,893)(28,019,181)(82,976)(2,744,184)(5,900)11,260,672(10)143,400 — — 143,390 Issuance of common stock to Graphite stockholders as a result of the Merger—— —— —— —— 8,320,485— 116,145 — — 116,145 Issuance of common stock from private placement, net—— —— —— —— 3,559,565— 49,840 — — 49,840 Reclassification of warrant liability to equity—— —— —— —— —— 1,918 — — 1,918 Merger transaction costs—— —— —— —— —— (5,146)— — (5,146)Unrealized loss on marketable securities—— —— —— —— —— — — (7)(7)Exercise of stock options and common warrants—— —— —— —— 383,898— 430 — — 430 Vesting of early exercised stock options—— —— —— —— 6,150— 10 — — 10 Share-based compensation—— —— —— —— —— 947 — — 947 Net loss—— —— —— —— —— — (16,648)— (16,648)Balance as of March 31,